BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 27287995)

  • 1. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
    Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
    Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
    Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
    World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
    Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
    Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-cancer-related survival benefit is associated with partial nephrectomy.
    Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
    Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
    Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
    BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Renal Functional Outcomes After Radical or Partial Nephrectomy for Renal Masses ≥7 cm Using the RENAL Score.
    Kopp RP; Liss MA; Mehrazin R; Wang S; Lee HJ; Jabaji R; Mirheydar HS; Gillis K; Patel N; Palazzi KL; Wan JY; Patterson AL; Derweesh IH
    Urology; 2015 Aug; 86(2):312-9. PubMed ID: 26189330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis.
    O'Malley RL; Hayn MH; Brewer KA; Underwood W; Hellenthal NJ; Kim HL; Sorokin I; Schwaab T
    World J Urol; 2015 Nov; 33(11):1807-14. PubMed ID: 25805189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
    Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
    Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of survival for partial vs. radical nephrectomy in young patients with T1a renal cell carcinoma treated at commission on cancer-accredited facilities and influence of comorbidities on treatment choice.
    Wang DC; Plante K; Stewart T; Wang D; Formica M; Daugherty M; Bratslavsky G
    Urol Oncol; 2017 Nov; 35(11):660.e9-660.e15. PubMed ID: 28736248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease.
    Takagi T; Kondo T; Omae K; Iizuka J; Kobayashi H; Yoshida K; Hashimoto Y; Tanabe K
    Int Urol Nephrol; 2016 Sep; 48(9):1421-7. PubMed ID: 27193433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.
    Gershman B; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    Eur Urol; 2018 Dec; 74(6):825-832. PubMed ID: 30262341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preserving Renal Function through Partial Nephrectomy Depends on Tumor Complexity in T1b Renal Tumors.
    Yoo S; You D; Jeong IG; Hong B; Hong JH; Kim CS; Ahn H; Song C
    J Korean Med Sci; 2017 Mar; 32(3):495-501. PubMed ID: 28145654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
    Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
    Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.